In breast cancer, the silencing of SORBS1 promotes epithelial-to-mesenchymal transition and confers a loss of sensitivity to chemotherapeutic agents such as cisplatin by inhibiting the activity of p53 [35]. Here, SORBS1 is linked to breast cancer.